Dr. Gregory A. PrinceFinancial Advisory Board / Scientific Advisory Board
Dr. Prince pioneered the prevention of the respiratory syncytial virus (RSV) disease in high-risk infants through the use of monoclonal antibody (Synagis®. is currently marketed through a partnership between MedImmune and Abbvie).
Dr. Prince brings pharmaceutical research and development and commercialization expertise to the Scientific Advisory Board team.
After earning doctorate degrees at UCLA (DDS, 1973; PhD, 1975) and serving a post-doctoral fellowship at the National Institutes of Health, Dr. Prince spent four decades in virology research, with a focus on the respiratory syncytial virus (RSV). He pioneered the prevention of RSV disease in high-risk infants, and as co-founder and CEO of Virion Systems, Inc. worked with MedImmune (acquired by AstraZeneca in 2007) to develop Synagis®. AstraZeneca markets Synagis within the United States, while AbbVie markets Synagis in all other regions.
Dixie State University-St. George, Utah inducted Dr. Prince to its Hall of Fame in 1999, in recognition of his scientific achievements, and later in 2012, the university granted him an honorary Doctorate of Humanities. Dr. Prince serves on the national advisory councils at four universities, and as the governor of Wesley Theological Seminary in Washington, D.C. He holds adjunct professorships at UCLA and Dixie State University and currently serves as Chief Scientific Officer at Soft Cell Biological Research, LLC. National Advisory Councils, Johns Hopkins University School of Education, Utah Valley University, Dixie State University (chair); author of over 150 scientific publications in the field of infectious diseases.